Differences in complement-dependent chemotactic activity generated by bullous pemphigoid and epidermolysis bullosa acquisita immune complexes: demonstration by leukocytic attachment and organ culture methods.
Bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA) are chronic blistering diseases associated with circulating complement (C)-binding anti-basement membrane zone (BMZ) antibodies and tissue-deposited immune complexes at the BMZ. Experimental evidence supporting a role for C-activating immune complexes in the pathogenesis of dermal inflammation and blisters has been reported in BP but not in EBA. In this study tissue-deposited immune complexes composed of EBA or BP antibodies were tested for generation of C-dependent chemotactic activity and the capacity to cause dermal leukocyte infiltration and dermal-epidermal separation (DES). Chemotactic activity was measured by the leukocyte attachment (LA) method. The capacity of complexes to mediate leukocyte infiltration and DES was examined in vitro using a newly described organ culture method. The results of LA showed immune complexes formed in vivo in EBA skin or in vitro by treating normal human skin with EBA antibodies were significantly more active in mediating C-dependent chemotaxis than complexes in BP skin or those formed with BP antibodies of equivalent or higher C-binding titers. Furthermore EBA antibodies and C caused leukocyte infiltration and DES in organ culture while BP antibodies did not. These results support a role for C-binding anti-BMZ antibodies in the pathogenesis of EBA lesions and demonstrate differences in the capacity of BP and EBA immune complexes to generate C-dependent chemotactic activity. These results suggest factors in addition to C-binding titers are important in the activation of C by BP and EBA immune complexes and suggest chemotactic factors other than those derived from C activation may be important in the recruitment of leukocytes in BP.
D000906:Antibodies / Q000032:analysis; D000936:Antigen-Antibody Complex / Q000032:analysis*; D001485:Basement Membrane / Q000276:immunology; D001666:Binding Sites, Antibody; D002464:Cell Migration Inhibition; D002634:Chemotaxis, Leukocyte; D003167:Complement Activation; D003165:Complement System Proteins / Q000032:analysis*; D004820:Epidermolysis Bullosa / Q000276:immunology*; D005455:Fluorescent Antibody Technique; D006801:Humans; D007962:Leukocytes / Q000276:immunology; D009924:Organ Culture Techniques; D010391:Pemphigoid, Bullous / Q000276:immunology*; D012867:Skin / Q000276:immunology; D012872:Skin Diseases, Vesiculobullous / Q000276:immunology*
D000906:Antibodies; D000936:Antigen-Antibody Complex; D003165:Complement System Proteins